Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Juergen Wolf

Showing results (21-30 of 38) with videos related to

Pageof 4
Sort By:
NPJ Precision Oncology|November 11, 2024
Benchmark of screening markers for KEAP1/NFE2L2 mutations and joint analysis with the K1N2-scoreChristoph Arolt, Andreas H Scheel, Margaret Dugan, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|March 3, 2019
Afatinib in NSCLC With HER2 Mutations: Results of the Prospective, Open-Label Phase II NICHE Trial of European Thoracic Oncology Platform (ETOP)Rafal Dziadziuszko, Egbert F Smit, Urania Dafni, et al.
Cancer Discovery|February 8, 2020
Pan-Cancer Efficacy of Vemurafenib in <i>BRAF</i> <sup>V600</sup>-Mutant Non-Melanoma CancersVivek Subbiah, Igor Puzanov, Jean-Yves Blay, et al.
The Lancet. Respiratory Medicine|January 20, 2020
Safety and efficacy of nazartinib (EGF816) in adults with EGFR-mutant non-small-cell lung carcinoma: a multicentre, open-label, phase 1 studyDaniel S-W Tan, Natasha B Leighl, Gregory J Riely, et al.
Lung Cancer (Amsterdam, Netherlands)|May 19, 2024
Capmatinib plus nivolumab in pretreated patients with EGFR wild-type advanced non-small cell lung cancerEnriqueta Felip, Giulio Metro, Daniel S W Tan, et al.
JAMA|May 12, 2017
Selumetinib Plus Docetaxel Compared With Docetaxel Alone and Progression-Free Survival in Patients With KRAS-Mutant Advanced Non-Small Cell Lung Cancer: The SELECT-1 Randomized Clinical TrialPasi A Jänne, Michel M van den Heuvel, Fabrice Barlesi, et al.
Lung Cancer (Amsterdam, Netherlands)|December 1, 2020
Detection of circulating tumor DNA by digital droplet PCR in resectable lung cancer as a predictive tool for recurrenceAsmae Gassa, Jana Fassunke, Sarah Schueten, et al.
European Journal of Cancer (Oxford, England : 1990)|June 28, 2024
Indirect comparison of capmatinib treatment from GEOMETRY mono-1 trial to SOC in German patients with locally advanced or metastatic NSCLC harboring METex14 skipping mutationsAnna Kron, Matthias Scheffler, Marcel Wiesweg, et al.
European Journal of Cancer (Oxford, England : 1990)|February 7, 2020
CheckMate 171: A phase 2 trial of nivolumab in patients with previously treated advanced squamous non-small cell lung cancer, including ECOG PS 2 and elderly populationsEnriqueta Felip, Andrea Ardizzoni, Tudor Ciuleanu, et al.
Cancer Research|May 20, 2018
Combined VEGF and PD-L1 Blockade Displays Synergistic Treatment Effects in an Autochthonous Mouse Model of Small Cell Lung CancerLydia Meder, Philipp Schuldt, Martin Thelen, et al.
Pageof 4

Showing results (21-30 of 38) with videos related to

Sort By:
Pageof 4
NPJ Precision Oncology|November 11, 2024
Benchmark of screening markers for KEAP1/NFE2L2 mutations and joint analysis with the K1N2-scoreChristoph Arolt, Andreas H Scheel, Margaret Dugan, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|March 3, 2019
Afatinib in NSCLC With HER2 Mutations: Results of the Prospective, Open-Label Phase II NICHE Trial of European Thoracic Oncology Platform (ETOP)Rafal Dziadziuszko, Egbert F Smit, Urania Dafni, et al.
Cancer Discovery|February 8, 2020
Pan-Cancer Efficacy of Vemurafenib in <i>BRAF</i> <sup>V600</sup>-Mutant Non-Melanoma CancersVivek Subbiah, Igor Puzanov, Jean-Yves Blay, et al.
The Lancet. Respiratory Medicine|January 20, 2020
Safety and efficacy of nazartinib (EGF816) in adults with EGFR-mutant non-small-cell lung carcinoma: a multicentre, open-label, phase 1 studyDaniel S-W Tan, Natasha B Leighl, Gregory J Riely, et al.
Lung Cancer (Amsterdam, Netherlands)|May 19, 2024
Capmatinib plus nivolumab in pretreated patients with EGFR wild-type advanced non-small cell lung cancerEnriqueta Felip, Giulio Metro, Daniel S W Tan, et al.
JAMA|May 12, 2017
Selumetinib Plus Docetaxel Compared With Docetaxel Alone and Progression-Free Survival in Patients With KRAS-Mutant Advanced Non-Small Cell Lung Cancer: The SELECT-1 Randomized Clinical TrialPasi A Jänne, Michel M van den Heuvel, Fabrice Barlesi, et al.
Lung Cancer (Amsterdam, Netherlands)|December 1, 2020
Detection of circulating tumor DNA by digital droplet PCR in resectable lung cancer as a predictive tool for recurrenceAsmae Gassa, Jana Fassunke, Sarah Schueten, et al.
European Journal of Cancer (Oxford, England : 1990)|June 28, 2024
Indirect comparison of capmatinib treatment from GEOMETRY mono-1 trial to SOC in German patients with locally advanced or metastatic NSCLC harboring METex14 skipping mutationsAnna Kron, Matthias Scheffler, Marcel Wiesweg, et al.
European Journal of Cancer (Oxford, England : 1990)|February 7, 2020
CheckMate 171: A phase 2 trial of nivolumab in patients with previously treated advanced squamous non-small cell lung cancer, including ECOG PS 2 and elderly populationsEnriqueta Felip, Andrea Ardizzoni, Tudor Ciuleanu, et al.
Cancer Research|May 20, 2018
Combined VEGF and PD-L1 Blockade Displays Synergistic Treatment Effects in an Autochthonous Mouse Model of Small Cell Lung CancerLydia Meder, Philipp Schuldt, Martin Thelen, et al.
Pageof 4